Osamu Iizuka

Medmain, Inc. provides a total solution for pathology diagnosis, from digitization of pathological specimens to support for pathological diagnosis using their own software. The company is based in Fukuoka, Japan. The Japanese company aims to create a better medical environment for all medical professionals around the world by utilizing cutting-edge technology to reduce the burden on the medical field that is increasing due to the chronic shortage of pathologists. The company was founded in 2018 by Osamu Iizuka. Osamu Iizuka has been the CEO since 2018.

Medmain, Inc. provides a total solution for pathology diagnosis, from digitization of pathological specimens to support for pathological diagnosis using their own software. The company is based in Fukuoka, Japan. The Japanese company aims to create a better medical environment for all medical professionals around the world by utilizing cutting-edge technology to reduce the burden on the medical field that is increasing due to the chronic shortage of pathologists. The company was founded in 2018 by Osamu Iizuka. Osamu Iizuka has been the CEO since 2018.

Medmain, Inc. provides a total solution for pathology diagnosis, from digitization of pathological specimens to support for pathological diagnosis using their own software. The company is based in Fukuoka, Japan. The Japanese company aims to create a better medical environment for all medical professionals around the world by utilizing cutting-edge technology to reduce the burden on the medical field that is increasing due to the chronic shortage of pathologists. The company was founded in 2018 by Osamu Iizuka. Osamu Iizuka has been the CEO since 2018.

Medmain, Inc. provides a total solution for pathology diagnosis, from digitization of pathological specimens to support for pathological diagnosis using their own software. The company is based in Fukuoka, Japan. The Japanese company aims to create a better medical environment for all medical professionals around the world by utilizing cutting-edge technology to reduce the burden on the medical field that is increasing due to the chronic shortage of pathologists. The company was founded in 2018 by Osamu Iizuka. Osamu Iizuka has been the CEO since 2018.